- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Myriad's Gene Panel Could Diagnose Metastatic Melanoma
The 23-gene diagnostic panel called myPath Melanoma could be used in addition to microscopy to distinguish the benign form of the disease from malignant disease.
A new 23-gene signature test (
, Myriad Genetics) could be helpful in these instances, researchers working with the company suggest.
The test was developed with a training set and then validated in an independent cohort. The results were
March 2 in the
.
Differentiating between malignant melanoma and benign skin moles can be difficult in about 15% of cases, where histopathologic analysis is not straightforward because of ambiguous findings. myPath Melanomapublished online Journal of Cutaneous Pathology
"myPath Melanoma is a powerful new molecular diagnostic test that analyzes genetic information inside skin cells to help us understand the biology of a patient's skin lesion and objectively differentiate benign moles from potentially lethal melanomas," researcher Loren Clarke, MD, medical director for dermatology at Myriad, said in a company press release.
"It is a tool for a pathologist to be used as an adjunct to microscopy," he told
.
Link to the article on Medscape:
Medscape Medical News
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
